January 2026 Content Release Notes Copied

01/22/20262026 ContentContent releasePhysician, Clinical, Admin, Billing

Problem Groups

Updates

The Problems > Add Details area is updated with applicable documentation points for the following diagnoses.

ERRB2 (HER2) mutation status has been updated for Lung Cancer, Non-small Cell (NSCLC) with the following documentation points:

  • TKD mutation
  • Non-TKD activating mutation (e.g., S310F/Y)
  • Wild type
  • Other non-actionable finding
  • Unknown

Histopathologic Type has been updated for Lung Cancer, Small Cell (SCLC) with the following documentation points:

  • Small cell lung carcinoma
  • Combined small cell carcinoma
  • Unknown

Lab Analytes & Panels

Additions

  • ACTH stimulation cortisol response comment
  • Auto WBC morphology
  • Beta 2 microglobulin/creatinine ratio, mcg/g creat
  • C3 Function, U/mL
  • Invitae JAK2 panel
  • Invitae TTR panel
  • Neo comprehensive myeloid disorders (plus FLT3 by PCR) panel
  • NeoTYPE ALL profile panel
  • Phosphorylated TAU-217 comment
  • Phosphorylated TAU-217, pg/mL
  • Phosphorylated TAU217(pTAU217) panel
  • Platelet comment
  • Tempus 1p19q FISH addendum report
  • Tempus 1p19q FISH amendment report
  • Tempus 1p19q FISH report
  • Tempus CancerNext + RNAinsight addendum report
  • Tempus CancerNext + RNAinsight amendment report
  • Tempus CancerNext + RNAinsight report
  • Tempus CancerNext addendum report
  • Tempus CancerNext amendment report
  • Tempus CancerNext expanded + RNAinsight addendum report
  • Tempus CancerNext expanded + RNAinsight amendment report
  • Tempus CancerNext expanded + RNAinsight report
  • Tempus CancerNext report
  • Tempus claudin18 IHC FDA neogenomics addendum report
  • Tempus claudin18 IHC FDA neogenomics amendment report
  • Tempus claudin18 IHC FDA neogenomics report
  • Tempus CMET FDA neogenomics addendum report
  • Tempus CMET FDA neogenomics amendment report
  • Tempus CMET FDA neogenomics report
  • Tempus DPYD addendum report
  • Tempus DPYD amendment report
  • Tempus DPYD report
  • Tempus familial variant testing addendum report
  • Tempus familial variant testing amendment report
  • Tempus familial variant testing report
  • Tempus FOLR1 IHC addendum report
  • Tempus FOLR1 IHC amendment report
  • Tempus FOLR1 IHC report
  • Tempus HER2 FISH addendum report
  • Tempus HER2 FISH amendment report
  • Tempus HER2 FISH report
  • Tempus HER2 IHC addendum report
  • Tempus HER2 IHC amendment report
  • Tempus HER2 IHC report
  • Tempus HRD addendum report
  • Tempus HRD amendment report
  • Tempus HRD report
  • Tempus immune profile score addendum report
  • Tempus immune profile score amendment report
  • Tempus immune profile score report
  • Tempus MGMT methylation addendum report
  • Tempus MGMT methylation amendment report
  • Tempus MGMT methylation report
  • Tempus MMR addendum report
  • Tempus MMR amendment report
  • Tempus MMR report
  • Tempus PD-L1 22C3 addendum report
  • Tempus PD-L1 22C3 amendment report
  • Tempus PD-L1 22C3 report
  • Tempus PD-L1 28-8 addendum report
  • Tempus PD-L1 28-8 amendment report
  • Tempus PD-L1 28-8 report
  • Tempus PD-L1 SP142 addendum report
  • Tempus PD-L1 SP142 amendment report
  • Tempus PD-L1 SP142 report
  • Tempus PD-L1 SP263 addendum report
  • Tempus PD-L1 SP263 amendment report
  • Tempus PD-L1 SP263 report
  • Tempus PLUS CancerNext expanded addendum report
  • Tempus PLUS CancerNext expanded amendment report
  • Tempus PLUS CancerNext expanded report
  • Tempus PTEN addendum report
  • Tempus PTEN amendment report
  • Tempus PTEN report
  • Tempus PURIST addendum report
  • Tempus PURIST amendment report
  • Tempus PURIST report
  • Tempus report summary addendum report
  • Tempus report summary amendment report
  • Tempus report summary report
  • Tempus TO addendum report
  • Tempus TO amendment report
  • Tempus TO report
  • Tempus UGT1A1 addendum report
  • Tempus UGT1A1 amendment report
  • Tempus UGT1A1 report
  • Tempus XE addendum report
  • Tempus XE amendment report
  • Tempus XE report
  • Tempus XF addendum report
  • Tempus XF amendment report
  • Tempus XF report
  • Tempus XG addendum report
  • Tempus XG amendment report
  • Tempus XG report
  • Tempus XM addendum report
  • Tempus XM amendment report
  • Tempus XM report
  • Tempus XR addendum report
  • Tempus XR amendment report
  • Tempus XR report
  • Tempus XT addendum report
  • Tempus XT amendment report
  • Tempus XT CDX addendum report
  • Tempus XT CDX amendment report
  • Tempus XT CDX report
  • Tempus XT report
  • Thinprep pap gross description
  • Voltage gated calcium channel (VGCC), type N & P/Q panel

Medications

Additions

  • Doxycycline Topical Gel
  • DS-8201a/ALT-BB4 invest Subcutaneous
  • LY3866288 invest Oral
  • Pumitamig (BMS-986545) or Bevacizumab invest IV
  • Vepugratinib invest (LY3866288 invest Oral)

Updates

Medications Updates
ABBV-383 invest IV General Instructions removed; SIG Instructions “day 1 of every 28-day cycle” removed

  • No instructions will display
BCA101 invest IV New Chemical Name available:

  • Ficerafusp Alfa invest

New Form available:

  • 375 mg recon soln
denosumab-qbde Subcutaneous (120 mg/1.7 mL – Xtrenbo) New SIGs available:

  • Denosumab-qbde 120 mg subcutaneously every 4 weeks
  • Denosumab-qbde 120 mg subcutaneously once
denosumab-qbde Subcutaneous (60 mg/mL – Enoby) New SIGs available:

  • Denosumab-qbde 60 mg subcutaneously every 6 months
  • Denosumab-qbde 60 mg subcutaneously once

 
Ferrous Sulfate Oral ER Tab
  • Removed default Form:
    142 mg (45 mg iron) ER tablet
    G2 will now default to the lowest form: 137 mg ER tablet.
  • Removed default SIG:
    142 mg orally, twice daily
    Dose and Frequency fields will be blank, allowing users to enter any amount with any selected form.
GSK5764227 invest IV Removed Form:

  • 100 mg solution

New Form available:

  • 100 mg recon soln

Instructions moved to SIG option:

  • 0 mg/kg intravenously As Directed; First infusion over 90 minutes. If well tolerated, subsequent infusions over 60 minutes.
PF-08046054 (SGN-PDL1V) invest IV

 

 New SIGs available:

  • 0 mg/kg AIBW intravenously once
  • 1.25 mg/kg AIBW intravenously once
  • 1.5 mg/kg AIBW intravenously once
PF-08634404 invest IV New SIG available:

  • 5 mg/kg intravenously once
Sigvotatug vedotin invest (SGN-B6A invest IV)

 

 New Form available:

  • 30 mg recon soln

New SIGs available:

  • 0 mg/kg AIBW intravenously once
  • 1.5 mg/kg AIBW intravenously once
  • 1.8 mg/kg AIBW intravenously once

Regimen Library

Additions

Regimen Name Diagnosis
Capecitabine D1-14 + Cisplatin + Pembrolizumab SQ Q21D Esophageal Cancer (Parent)​; ​Gastric Cancer
Capecitabine D1-14 + Cisplatin + Trastuzumab IV + Pembrolizumab SQ Q21D Esophageal Cancer (Parent)​; ​Gastric Cancer
Capecitabine D1-14 + Oxaliplatin (XELOX/CAPOX) + Trastuzumab IV + Pembrolizumab SQ Q21D Esophageal Cancer (Parent)​; ​Gastric Cancer
Daratumumab SQ + Lenalidomide + Dexamethasone Q28D Maintenance (Non-Transplant Candidates) (Part 2 of 2) Multiple Myeloma (MM)
Enfortumab vedotin-ejfv (Padcev) D1,8 + Pembrolizumab SQ Q21D (Neoadjuvant) Bladder Cancer; Renal Pelvis and Ureter Cancer; Urethral Cancer​
Enfortumab vedotin-ejfv (Padcev) D1,8 + Pembrolizumab Q21D (Neoadjuvant) Bladder Cancer; Renal Pelvis and Ureter Cancer; Urethral Cancer
Enfortumab vedotin-ejfv (Padcev) D1,8 + Pembrolizumab Q21D fb Pembrolizumab Q21D (Adjuvant) Bladder Cancer; Renal Pelvis and Ureter Cancer; Urethral Cancer​
Enfortumab vedotin-ejfv (Padcev) D1,8 + Pembrolizumab SQ Q21D fb Pembrolizumab SQ Q21D (Adjuvant) Bladder Cancer; Renal Pelvis and Ureter Cancer; Urethral Cancer​
Enfortumab vedotin-ejfv (Padcev) D1,8,22,29 + Pembrolizumab Q42D fb Pembrolizumab Q42D (Adjuvant) Bladder Cancer; Renal Pelvis and Ureter Cancer; Urethral Cancer​
Enfortumab vedotin-ejfv (Padcev) D1,8,22,29 + Pembrolizumab SQ Q42D fb Pembrolizumab SQ Q42D (Adjuvant) ​​Bladder Cancer; Renal Pelvis and Ureter Cancer; Urethral Cancer​
Epcoritamab-bysp (Epkinly) SQ D1,8,15,22 fb D1 + Lenalidomide D1-21 + Rituximab IV C1-5 Q28D Lymphoma, Non-Hodgkin (NHL) (Parent)
Fluorouracil CIV D1-5 + Cisplatin + Pembrolizumab SQ Q21D Esophageal Cancer (Parent)​; ​Gastric Cancer​
Fluorouracil CIV D1-5 + Cisplatin + Trastuzumab IV + Pembrolizumab SQ Q21D Esophageal Cancer (Parent)​; ​Gastric Cancer
Pembrolizumab SQ + AC Q21D fb Pembrolizumab SQ + Paclitaxel (Weekly) + Carboplatin (Weekly) Q21D Breast Cancer
Pembrolizumab SQ + AC Q21D fb Pembrolizumab SQ + Paclitaxel (Weekly) + Carboplatin Q21D Breast Cancer
Pembrolizumab SQ + AC (Q3W) Q42D fb Pembrolizumab SQ + Paclitaxel (Weekly) + Carboplatin (Q3W) Q42D Breast Cancer
Pembrolizumab SQ + Cisplatin + Fluorouracil CIV D1-4 Q21D (Part 1 of 2) Head and Neck Cancer (Parent)​
Pembrolizumab SQ + Cisplatin + RT fb Pembrolizumab SQ (Adjuvant Head and Neck) Head and Neck Cancer (Parent)​
Pembrolizumab SQ + Dabrafenib + Trametinib Q21D Melanoma, Skin
Pembrolizumab SQ + Docetaxel + Cisplatin Q21D (Part 1 of 2) ​​Head and Neck Cancer (Parent)​
Pembrolizumab SQ + Low-Dose Ipilimumab Q21D Melanoma, Skin
Pembrolizumab SQ + Paclitaxel (Weekly) + Carboplatin (Weekly) Q42D fb Pembrolizumab SQ + AC (Dose Dense) Q42D Breast Cancer
Pembrolizumab SQ + Paclitaxel (Weekly) + Carboplatin (Q3W) Q42D fb Pembrolizumab SQ + AC (Q3W) Q42D Breast Cancer
Pembrolizumab SQ + Paclitaxel (Weekly) + Carboplatin (Q3W) Q42D fb Pembrolizumab SQ + AC (Dose Dense) Q42D Breast Cancer
Pembrolizumab SQ + Paclitaxel + Cisplatin + Bevacizumab Q21D (Cervical) Cervical Cancer
Pembrolizumab SQ + Paclitaxel + Cisplatin Q21D (Cervical) Cervical Cancer
Pembrolizumab SQ + AC (Q3W) Q42D fb Pembrolizumab SQ + Paclitaxel (Weekly) + Carboplatin (Weekly) Q42D Breast Cancer
Pembrolizumab SQ + Pemetrexed + Carboplatin Q21D (Mesothelioma) ​​Malignant Mesothelioma; Malignant Pleural Mesothelioma​
Pembrolizumab SQ + Pemetrexed + Cisplatin Q21D (Mesothelioma) ​​Malignant Mesothelioma; Malignant Pleural Mesothelioma​
Pembrolizumab SQ + RT Q21D fb Pembrolizumab SQ Q21D (Adjuvant Head and Neck) ​​Head and Neck Cancer (Parent)​
Ziftomenib Q30D ​​Leukemia, Acute Myeloid (AML)​
Zopapogene imadenovec-drba D1,15,43,85 All Problems

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles

  • All Problems
  • Amyloidosis
  • Breast Cancer
  • Cutaneous Carcinoma, Squamous Cell
  • Fallopian Tube Cancer
  • Head and Neck Cancer (Parent)
  • Kaposi’s Sarcoma
  • Lymphoma, Hodgkin (HL)
  • Lymphoma, Non-Hodgkin (NHL) (Parent)
  • Lymphoma, Non-Hodgkin (NHL), Primary Cutaneous Lymphoma, Mycosis Fungoides/Sezary Syndrome
  • Multiple Myeloma (MM)
  • Ovarian and Primary Peritoneal Cancer
  • Solid Tumors (Parent) (excluding HL/NHL/ including Solid Other)
  • Solid Tumors (Parent) (including Solid Other/HL)
  • Uterine Cancer (Parent)

Renames

Previous Name New Name
Daratumumab IV + Lenalidomide + Bortezomib D1,4,8,11 + Dexamethasone (RVD) Q21D (Part 1 of 2) Daratumumab IV + Lenalidomide + Bortezomib D1,4,8,11 + Dexamethasone (RVD) Q21D (Transplant Candidates)
Daratumumab IV + Lenalidomide + Bortezomib D1,4,8,11 + Dexamethasone (RVD) Q21D (Part 1 of 2: C1 Split Dosing) Daratumumab IV + Lenalidomide + Bortezomib D1,4,8,11 + Dexamethasone (RVD) Q21D (C1 Split Dosing) (Transplant Candidates)
Daratumumab IV + Lenalidomide + Bortezomib D1,8,15 + Dexamethasone (RVD) Q21D (Part 1 of 2) Daratumumab IV + Lenalidomide + Bortezomib D1,8,15 + Dexamethasone (RVD) Q21D (Transplant Candidates)
Daratumumab IV + Lenalidomide + Bortezomib D1,8,15 + Dexamethasone (RVD) Q21D (Part 1 of 2: C1 Split Dosing) Daratumumab IV + Lenalidomide + Bortezomib D1,8,15 + Dexamethasone (RVD) Q21D (C1 Split Dosing) (Transplant Candidates)
Daratumumab SQ + Lenalidomide + Bortezomib D1,4,8,11 + Dexamethasone (RVD) Q21D (Part 1 of 2) Daratumumab SQ + Lenalidomide + Bortezomib D1,4,8,11 + Dexamethasone (RVD) Q21D (Non-Transplant Candidates) (Part 1 of 2)
Daratumumab SQ + Lenalidomide + Bortezomib D1,4,8,11 + Dexamethasone (RVD) (PERSEUS) Q28D (Part 1 of 2) Daratumumab SQ + Lenalidomide + Bortezomib D1,4,8,11 + Dexamethasone (RVD) (PERSEUS) Q28D (Transplant Candidates)
Daratumumab SQ + Lenalidomide + Bortezomib D1,8,15 + Dexamethasone (RVD) Q21D (Part 1 of 2) Daratumumab SQ + Lenalidomide + Bortezomib D1,8,15 + Dexamethasone (RVD) Q21D (Non-Transplant Candidates) (Part 1 of 2)
Daratumumab SQ + Lenalidomide + Bortezomib D1,8,15,22 + Dexamethasone (RVD) (PERSEUS) Q28D (Part 1 of 2) Daratumumab SQ + Lenalidomide + Bortezomib D1,8,15,22 + Dexamethasone (RVD) (PERSEUS) Q28D (Transplant Candidates)

Removals

Regimen Name Diagnosis
Paclitaxel D1,8,15 + Pertuzumab and Trastuzumab SQ (Phesgo) Q21D (Neoadjuvant) Paclitaxel D1,8,15 + Pertuzumab and Trastuzumab SQ (Phesgo) Q21D (Neoadjuvant/Adjuvant)
Paclitaxel D1,8,15 + Trastuzumab IV + Pertuzumab IV Q21D (Neoadjuvant) Paclitaxel D1,8,15 + Trastuzumab IV + Pertuzumab IV Q21D (Neoadjuvant/Adjuvant)

Billing & HCPCS Codes

Additions

Medication HCPCS Codes
Denosumab-qbde Subcutaneous (120 mg/1.7 mL – Xtrenbo) J3590 per 120 mg
Denosumab-qbde Subcutaneous (60 mg/mL – Enoby) J3590 per 60 mg

 

NDC – HCPCS Crosswalk: Current Procedural Terminology (CPT)

Updates

Code Description
10040 EXTRACTION
11730 AVULSION NAIL PLATE SIMPLE 1
11732 AVLSN NAIL PLATE SIMPLE EACH